Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Director Aron Shapiro Buys 3,000 Shares

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Director Aron Shapiro bought 3,000 shares of the stock in a transaction on Tuesday, September 10th. The stock was purchased at an average cost of $3.60 per share, for a total transaction of $10,800.00. Following the acquisition, the director now directly owns 3,000 shares of the company’s stock, valued at approximately $10,800. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Kiora Pharmaceuticals Stock Performance

Shares of NASDAQ:KPRX opened at $3.58 on Thursday. The stock’s fifty day simple moving average is $3.99 and its 200-day simple moving average is $4.89. Kiora Pharmaceuticals, Inc. has a 52-week low of $3.00 and a 52-week high of $8.98.

Kiora Pharmaceuticals (NASDAQ:KPRX) last released its earnings results on Friday, August 9th. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.95) by $0.42. The business had revenue of $0.02 million for the quarter. On average, equities research analysts anticipate that Kiora Pharmaceuticals, Inc. will post 1.17 EPS for the current fiscal year.

Hedge Funds Weigh In On Kiora Pharmaceuticals

An institutional investor recently bought a new position in Kiora Pharmaceuticals stock. Rosalind Advisors Inc. bought a new position in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 2,300,000 shares of the company’s stock, valued at approximately $1,624,000. Kiora Pharmaceuticals accounts for 1.5% of Rosalind Advisors Inc.’s holdings, making the stock its 22nd biggest holding. Rosalind Advisors Inc. owned about 8.76% of Kiora Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 76.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on KPRX. Maxim Group raised Kiora Pharmaceuticals to a “strong-buy” rating in a report on Thursday, June 13th. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Kiora Pharmaceuticals in a research report on Thursday, August 22nd.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.